Abstract
Objective: High smoking rates in adults with attention-deficit/ hyperactivity disorder (ADHD) and nicotine's amelioration of ADHD suggest that effective ADHD treatment might facilitate abstinence in smokers with ADHD. The present study evaluated if using osmotic-release oral system methylphenidate (OROS-MPH) to treat ADHD enhances response to smoking cessation treatment in smokers with ADHD. Method: A randomized, double-blind, placebocontrolled, 11-week trial with a 1-month follow-up was conducted at 6 clinical sites between December 2005 and January 2008. Adults (aged 18-55 years) meeting DSM-IV criteria for ADHD and interested in quitting smoking were randomly assigned to OROS-MPH titrated to 72 mg/d (n = 127) or placebo (n = 128). All participants received brief weekly individual smoking cessation counseling for 11 weeks and 21 mg/d nicotine patches starting on the smoking quit day (day 27) through study week 11. Outcome measures included prolonged smoking abstinence and DSM-IV ADHD Rating Scale (ADHD-RS) score. Results: Of 255 randomly assigned participants, 204 (80%) completed the trial. Prolonged abstinence rates, 43.3% and 42.2%, for the OROS-MPH and placebo groups, respectively, did not differ significantly (OR = 1.1; 95% CI, 0.63-1.79; P = .81). Relative to placebo, OROS-MPH evidenced a greater reduction in DSM-IV ADHD-RS score (P < .0001) and in cigarettes per day during the post-quit phase (P = .016). Relative to placebo, OROS-MPH increased blood pressure and heart rate to a statistically, but not clinically, significant degree (P < .05); medication discontinuation did not differ significantly between treatments. Conclusions: Treatment for ADHD did not improve smoking cessation success; OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated in this healthy sample of adult ADHD smokers. Trial Registration: clinical trials.gov Identifier: NCT00253747.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1680-1688 |
| Number of pages | 9 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 71 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2010 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers : A randomized, double-blind, placebo-controlled trial. / Winhusen, Theresa M.; Somoza, Eugene C.; Brigham, Gregory S.; Liu, David S.; Green, Carla A.; Covey, Lirio S.; Croghan, Ivana T; Adler, Lenard A.; Weiss, Roger D.; Leimberger, Jeffrey D.; Lewis, Daniel F.; Dorer, Emily M.
In: Journal of Clinical Psychiatry, Vol. 71, No. 12, 12.2010, p. 1680-1688.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers
T2 - A randomized, double-blind, placebo-controlled trial
AU - Winhusen, Theresa M.
AU - Somoza, Eugene C.
AU - Brigham, Gregory S.
AU - Liu, David S.
AU - Green, Carla A.
AU - Covey, Lirio S.
AU - Croghan, Ivana T
AU - Adler, Lenard A.
AU - Weiss, Roger D.
AU - Leimberger, Jeffrey D.
AU - Lewis, Daniel F.
AU - Dorer, Emily M.
PY - 2010/12
Y1 - 2010/12
N2 - Objective: High smoking rates in adults with attention-deficit/ hyperactivity disorder (ADHD) and nicotine's amelioration of ADHD suggest that effective ADHD treatment might facilitate abstinence in smokers with ADHD. The present study evaluated if using osmotic-release oral system methylphenidate (OROS-MPH) to treat ADHD enhances response to smoking cessation treatment in smokers with ADHD. Method: A randomized, double-blind, placebocontrolled, 11-week trial with a 1-month follow-up was conducted at 6 clinical sites between December 2005 and January 2008. Adults (aged 18-55 years) meeting DSM-IV criteria for ADHD and interested in quitting smoking were randomly assigned to OROS-MPH titrated to 72 mg/d (n = 127) or placebo (n = 128). All participants received brief weekly individual smoking cessation counseling for 11 weeks and 21 mg/d nicotine patches starting on the smoking quit day (day 27) through study week 11. Outcome measures included prolonged smoking abstinence and DSM-IV ADHD Rating Scale (ADHD-RS) score. Results: Of 255 randomly assigned participants, 204 (80%) completed the trial. Prolonged abstinence rates, 43.3% and 42.2%, for the OROS-MPH and placebo groups, respectively, did not differ significantly (OR = 1.1; 95% CI, 0.63-1.79; P = .81). Relative to placebo, OROS-MPH evidenced a greater reduction in DSM-IV ADHD-RS score (P < .0001) and in cigarettes per day during the post-quit phase (P = .016). Relative to placebo, OROS-MPH increased blood pressure and heart rate to a statistically, but not clinically, significant degree (P < .05); medication discontinuation did not differ significantly between treatments. Conclusions: Treatment for ADHD did not improve smoking cessation success; OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated in this healthy sample of adult ADHD smokers. Trial Registration: clinical trials.gov Identifier: NCT00253747.
AB - Objective: High smoking rates in adults with attention-deficit/ hyperactivity disorder (ADHD) and nicotine's amelioration of ADHD suggest that effective ADHD treatment might facilitate abstinence in smokers with ADHD. The present study evaluated if using osmotic-release oral system methylphenidate (OROS-MPH) to treat ADHD enhances response to smoking cessation treatment in smokers with ADHD. Method: A randomized, double-blind, placebocontrolled, 11-week trial with a 1-month follow-up was conducted at 6 clinical sites between December 2005 and January 2008. Adults (aged 18-55 years) meeting DSM-IV criteria for ADHD and interested in quitting smoking were randomly assigned to OROS-MPH titrated to 72 mg/d (n = 127) or placebo (n = 128). All participants received brief weekly individual smoking cessation counseling for 11 weeks and 21 mg/d nicotine patches starting on the smoking quit day (day 27) through study week 11. Outcome measures included prolonged smoking abstinence and DSM-IV ADHD Rating Scale (ADHD-RS) score. Results: Of 255 randomly assigned participants, 204 (80%) completed the trial. Prolonged abstinence rates, 43.3% and 42.2%, for the OROS-MPH and placebo groups, respectively, did not differ significantly (OR = 1.1; 95% CI, 0.63-1.79; P = .81). Relative to placebo, OROS-MPH evidenced a greater reduction in DSM-IV ADHD-RS score (P < .0001) and in cigarettes per day during the post-quit phase (P = .016). Relative to placebo, OROS-MPH increased blood pressure and heart rate to a statistically, but not clinically, significant degree (P < .05); medication discontinuation did not differ significantly between treatments. Conclusions: Treatment for ADHD did not improve smoking cessation success; OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated in this healthy sample of adult ADHD smokers. Trial Registration: clinical trials.gov Identifier: NCT00253747.
UR - http://www.scopus.com/inward/record.url?scp=78650464201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650464201&partnerID=8YFLogxK
U2 - 10.4088/JCP.09m05089gry
DO - 10.4088/JCP.09m05089gry
M3 - Article
VL - 71
SP - 1680
EP - 1688
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
SN - 0160-6689
IS - 12
ER -